ACQUISITIONS ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2012

InfuScience, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table summarizes the identifiable intangible assets acquired (in thousands):

	Weighted-  Average  Useful Lives  (Months)	Amounts Recognized as of Acquisition Date (in thousands)
InfuScience customer relationships	5	400
Total identifiable intangible assets acquired	5	$	400

Schedule of Purchase Price Allocation [Table Text Block]

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date. Due to the timing of this acquisition, these amounts are provisional and subject to change. The Company will finalize these amounts as it obtains the information necessary to complete the measurement process. Any changes resulting from facts and circumstances that existed as of the acquisition date may result in retrospective adjustments to the provisional amounts recognized at the acquisition date. These changes could be significant. The Company will finalize these amounts no later than one year from the acquisition date.

	Amounts Recognized as of Acquisition Date (in thousands)
Cash	$	23
Accounts receivable	4,938
Inventories	586
Other current assets	371
Property and equipment	751
Identifiable intangible assets	400
Other non-current assets	349
Current liabilities	(4,422		)
Total identifiable net assets	2,996
Goodwill	38,423
Total assets and total consideration transferred	$	41,419

DS Pharmacy, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table summarizes the identifiable intangible assets acquired (in thousands):

	Estimated
	Useful Life	Fair Value
Customer list	6 months	$	270
Transitional services contract	1 year	1,040
License and marketing related intangibles	6 years	7,359
		$	8,669

Schedule of Purchase Price Allocation [Table Text Block]

The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of DS Pharmacy (in thousands):

Inventory	$	469
Property and equipment	76
Tangible assets acquired			$	545
Intangible assets acquired			8,669
Total assets and total consideration			$	9,214

Critical Homecare Solutions Holdings, Inc. [Member]

Business Acquisition [Line Items]

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

The following table summarizes the identifiable intangible assets acquired (in thousands):

	Estimated
	Useful Life	Fair Value
Trademarks/trade names	various	$	8,400
Infusion customer relationships	3 years	7,200
Certificates of need	indefinite	9,600
		$	25,200

Schedule of Purchase Price Allocation [Table Text Block]

The following table sets forth the fair value of the assets acquired and liabilities assumed as a result of the acquisition of CHS (in thousands):

Cash and cash equivalents	$	7,162
Receivables	38,289
Deferred taxes	6,228
Other current assets	4,993
Property and equipment	6,462
Other assets	2,778
Total assets acquired				65,912
Accounts payable	(3,334		)
Notes payable	(2,250		)
Amounts due to plan sponsors	(8,763		)
Accrued expenses and other current liabilities	(34,002		)
Deferred tax liabilities	(7,144		)
Total liabilities assumed				(55,493		)
Tangible assets acquired, net				$	10,419
Intangible assets acquired				25,200
Debt assumed				(128,952		)
Goodwill				299,643
Total consideration conveyed to CHS stockholders				$	206,310

Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]

The following table sets forth the consideration transferred in connection with the acquisition of CHS and the aggregate purchase price allocation as of March 25, 2010 (in thousands):

Fair value of equity consideration:
BioScrip common stock issued (13.1 million shares)	$	91,614
BioScrip warrants issued (3.4 million warrants)	12,268
Rollover options (716,086 options)	2,802
Cash paid to CHS stockholders	99,626
Total consideration conveyed to CHS stockholders	$	206,310
Cash paid for merger related expenses incurred by CHS	14,566
Assumption and repayment of CHS debt	128,952
Total amounts paid to execute the merger of CHS	$	349,828

DS Pharmacy and Crictal Homecare [Member]

Business Acquisition [Line Items]

Business Acquisition, Pro Forma Information [Table Text Block]

Amounts are in thousands, except for earnings per share.

	Years Ended December 31,
	2012			2011			2010
Revenue	$	685,295		$	589,333		$	491,476
Net loss from continuing operations	$	(9,030	)	$	(1,523	)	$	(67,095	)
Basic loss per common share from continuing operations	$	(0.16	)	$	(0.03	)	$	(1.26	)
Diluted loss per common share from continuing operations	$	(0.16	)	$	(0.03	)	$	(1.26	)